摘要
目的：评价聚乙二醇干扰素α-2b联合利巴韦林治疗慢性丙型肝炎患者的疗效和安全性。方法：29例患者按2：1．随机化分配入组。治疗组20例，依体重不同每周1次皮下注射佩乐能40μg或50μg，同时口服利巴韦林750～1050mg／d；对照组9例，每周3次皮下注射甘乐能（3mu／次），利巴韦林的剂量和服法与治疗组相同。疗程48周。结果：治疗组和对照组持续病毒学应答率分别为85．00％和44．44％（P〈O．05）；不良事件发生率两组间无明显差异。结论：聚乙二醇干扰素α-2b联合利巴韦林治疗慢性丙型肝炎的疗效优于干扰素α-2b联合利巴韦林，安全性相似。
Objective To evaluate the therapeutic effect and safety of peginterferon alfa-2b plus ribavirin for chronic hepatitis C. Methods Twenty-nine patients with chronic hepatitis C were randomly divided into treatment group（n=20） and control group（n=9） in a 2 ： 1 ratio. The patients in the treatment group received 40 or 50 μg of peginterferon alfa-2b subcutaneously once a week plus ribavirin orally 750- 1050 mg per day for 48 weeks totally. The patients in control group received 3 million units of interferon alfa-2b subcutaneously three times a week plus ribavirin orally 750- 1050 mg per day for 48 weeks totally. Results At the end of the follow-up period, 85.00% of the patients in the treatment group, as compared with 44. 44 % in control group, had a sustained virologic response （P〈0. 05）. There was no significant difference between these two groups in the rate of adverse effect. Conclusion In the patients with chronic hepatitis C, a regimen of peginterferon alfa-2b given once a week plus ribavirin is more effective than that of interferon alfa-2b given three times a week plus ribavirin, with similar safety.
出处
《实用诊断与治疗杂志》
2006年第9期628-629,632,共3页
Journal of Practical Diagnosis and Therapy
